CPT® Code 96368

Add-On Code

Quick Reference

• Code definition: CPT 96368 reports a concurrent intravenous infusion, meaning a second (or additional) substance is infused simultaneously through the same IV access while a primary infusion is already running. It is an add-on code and must be listed separately in addition to the primary procedure code.
• Key billing rule: Maximum one unit per date of service (MUE = 1), regardless of how many drugs infuse simultaneously [3]. Reporting 2+ units triggers automated denial.
• Add-on code status: 96368 requires a primary infusion code on the same claim. Valid primaries include 96365, 96360, 96374, 96413, and other qualifying initial infusion codes. A standalone 96368 will reject [1].
• Modifier essentials: Modifier 51 does not apply (add-on code exemption). Modifier 25 belongs on any same-day E/M code, not on 96368 itself. Modifier 50 does not apply [1].
• Documentation must-have: Documented start and stop times for the concurrent infusion showing temporal overlap with the primary infusion. Without overlapping times in the nursing infusion record, there is no basis to distinguish concurrent (96368) from sequential (96367) [2].
• Top confusion point: Concurrent and sequential infusions are mutually exclusive for the same drug/time window. If one infusion ends before the next begins, the service is sequential (96367), not concurrent (96368). Misidentifying the timing relationship is the most common infusion coding error.
• Payer alert: Under Medicare OPPS, 96368 is APC-packaged; no separate payment is made to the facility. Professional claims from the physician are not affected by this packaging rule [5].

When to Use This Code

96368 applies when a second substance is infusing via IV at the same time as the primary infusion, with both start/stop times documented in the nursing record showing overlap. The concurrent drug is typically a supportive agent: antiemetics (ondansetron, prochlorperazine), corticosteroids (dexamethasone, methylprednisolone), antihistamines (diphenhydramine), or hydration (normal saline, lactated Ringer's) running alongside a primary therapeutic agent.

Clinical settings where 96368 is frequently billed:

• Oncology/infusion centers: Chemotherapy primary (96413) with a supportive antiemetic or steroid infusing simultaneously via Y-site or piggyback
• Rheumatology: Biologic infusion (96365) with concurrent pre-medication running during the infusion window
• Hospital outpatient/infusion centers: Any therapeutic infusion where a second drug is initiated before the primary drip ends
• Office-based infusion: Physician office (POS 11) concurrent antihistamine or hydration running alongside the primary agent

Scope boundaries: 96368 covers only IV infusion delivered as a drip (not IV push). If the concurrent drug is administered as a bolus push, 96375 (sequential IV push) or 96374 (initial IV push) applies depending on timing. 96368 does not apply in inpatient settings; infusion services bundle into the DRG.

No minimum time threshold: Unlike 96365 (which requires >15 minutes to be separately reportable), 96368 has no minimum infusion duration [1]. The concurrent drug only needs to be genuinely infusing at the same time as the primary service.

Hierarchy determination: The most resource-intensive, clinically primary substance takes the initial code. When chemotherapy is administered, 96413 is primary. When a biologic or other therapeutic drug is the focus, 96365 is primary. Hydration (96360) is lower in the hierarchy; if a therapeutic infusion runs at the same time as hydration, 96365 is initial and 96368 captures the concurrent hydration, not a separate 96360 [2].

Code Differentiation Table

The critical differentiator between 96368 and 96367 is clock-time overlap. Both are add-on codes for a new substance beyond the primary infusion, but 96368 requires documented temporal overlap; 96367 requires the prior infusion to have ended. A single infusion record with clear start/stop times resolves this distinction every time.

flowchart TD
    A[New IV substance administered] --> B{Is it a drip infusion?\nNot a push/bolus}
    B -- No --> C[IV push: 96374 initial\nor 96375 sequential]
    B -- Yes --> D{Was a primary IV infusion\nalready running?}
    D -- No --> E[Primary infusion:\n96365 or 96413]
    D -- Yes --> F{Did the primary infusion\nstop before this one started?}
    F -- Yes --> G[Sequential infusion:\n96367]
    F -- No, times overlap --> H[Concurrent infusion:\n96368 — one unit max per day]

Billing & Modifier Rules

Add-on code requirements: 96368 must appear on the same claim as a qualifying primary infusion code. Claims submitted with 96368 as the sole service will reject. Primary codes that support 96368 include 96360, 96365, 96366, 96374, 96413, and other qualifying initial infusion codes [1].

One-unit-only rule: AMA CPT guidelines cap 96368 at one unit per encounter [1]. CMS enforces this through an MUE of 1 per date of service [3]. If three drugs are infusing simultaneously (e.g., a chemo agent, an antiemetic, and a steroid), 96368 is reported once. Submitting multiple units will trigger denial at the claim-processing level.

Modifier 51: Does not apply. As an add-on code, 96368 is exempt from the multiple-procedure payment reduction (fee schedule indicator: 0, no payment adjustment for multiple procedures) [1].

Modifier 25: When a significant, separately identifiable E/M service is performed on the same day as the infusion, modifier 25 is appended to the E/M code, not to 96368 [1].

Modifier 59/XS: Generally not required; add-on codes are inherently distinct services. May be needed in isolated circumstances to override an inappropriate NCCI edit, with supporting documentation.

Modifier 50/bilateral: Does not apply (fee schedule indicator: 0) [1].

OPPS packaging (facility billing): In the hospital outpatient setting, CMS assigns 96368 an APC status of "Items and Services Packaged into APC Rates" [5]. Medicare does not make a separate APC payment; the value is absorbed into the primary service's APC. Facility coders should still report 96368 for accurate utilization data and cost tracking, but should not build separate payment into financial models for this code.

Bundling and NCCI: The NCCI Policy Manual Chapter 11 governs drug administration bundling [2]. When concurrent hydration is reported, 96368 captures the hydration running alongside the therapeutic infusion; reporting both 96360 and 96368 for the same overlapping hydration drip constitutes double billing. Verify current PTP edit pairs in the CMS NCCI tables, as these are updated annually.

Documentation Essentials

Required elements per CMS Chapter 12 and NCCI Policy Manual [2][4]:

• Drug name and specific substance (code descriptor requires "specify substance or drug")
• Dose and concentration
• Route of administration (intravenous)
• Start time and stop time for the concurrent infusion
• Documented temporal overlap with the primary infusion (start time of concurrent must precede stop time of primary)
• Signed, dated physician order for each drug
• Clinical indication for the concurrent drug
• Patient response or tolerance as documented by nursing or physician

Audit red flags specific to 96368:

• Missing or incomplete start/stop times: The single most common documentation failure. Auditors look for this first when reviewing infusion claims. Without overlapping times in the nursing flowsheet or infusion record, there is no evidentiary basis to distinguish 96368 from 96367. Recovery audit contractors routinely deny 96368 on this basis.
• No physician order for the concurrent drug: Each substance administered must have its own order. An infusion record showing drug administration without a corresponding order is a compliance exposure.
• Concurrent drug coded as the primary: If the most resource-intensive drug is placed on 96368 and a lower-acuity drug occupies the initial code, hierarchy is violated. Auditors flag this pattern, particularly in chemo encounters where 96413 should always be the primary when chemotherapy is administered.
• Drug charge mismatch: OIG has flagged claims where the HCPCS J-code for the drug does not match the administration code billed [8]. For 96368 specifically, the concurrent drug's J-code should be on the claim.

Medicare, Commercial & Medicaid Payer Rules

Medicare:

CMS does not have a standalone NCD or LCD governing infusion administration codes. Medical necessity derives from the underlying diagnosis and the drug administered [4]. MAC LCDs for specific drugs (e.g., biologics, infused oncology agents) apply to the therapeutic agent; 96368 rides on that medical necessity. Key Medicare-specific rules:

• MUE = 1 per date of service; enforced at the claim level [3]
• OPPS APC status: packaged; no separate facility payment [5]
• Professional billing under MPFS: BETOS classification P6C (Minor procedures, other); incident-to rules apply in the office setting
• Incident-to requirements for office-based infusion: physician physically present in the office suite, service within established plan of care, auxiliary personnel meet incident-to criteria, and direct supervision (physician immediately available) maintained throughout [4]
• Codes 96360 through 96379 are not intended to be reported by the physician in the facility setting [1]

Commercial payers:

Most commercial payers follow AMA CPT hierarchy and CMS bundling conventions for infusion codes, but coverage policies for the underlying drugs vary significantly. Prior authorization requirements attach to the drug (J-code), not the administration code. Verify payer-specific infusion policies for independent infusion centers (POS 19), as some payers restrict coverage or apply different reimbursement schedules outside the physician office.

Medicaid:

Medicaid infusion administration coverage varies by state. Managed Medicaid plans may impose prior authorization for the therapeutic agent or require specific place-of-service restrictions. Verify state MAC or managed plan policies before billing 96368 for Medicaid beneficiaries.

Common Denials & Prevention

Denial: Units exceed MUE

Reporting more than one unit of 96368 on the same date of service triggers automated denial at the MUE enforcement level [3]. Root cause is typically misunderstanding the one-unit rule. Prevention: train billing staff that 96368 is capped at 1 unit per DOS regardless of the number of concurrent drugs. Never submit 96368 x 2.

Denial: Add-on code without primary procedure

Claims with 96368 and no primary infusion code on the same date will reject. This occurs when the primary infusion service bills on a different claim or different date, or when a coder submits only the add-on. Prevention: confirm the primary code (96365, 96360, 96374, 96413, etc.) is on the same claim before submitting 96368.

Denial: Insufficient documentation (concurrent timing not established)

Auditors or post-payment reviewers deny 96368 when the medical record does not document overlapping start/stop times for the concurrent and primary infusions. Recovery audit contractors frequently target this. Prevention: ensure nursing infusion flowsheets record individual start and stop times per drug; do not rely solely on a narrative note without time stamps. On appeal, submit the infusion flowsheet with highlighted time entries.

Denial: Incorrect hierarchy (wrong code designated as primary)

When the clinically dominant drug is placed on 96368 rather than on an initial code, payers may question the coding or deny on hierarchy grounds [1]. Prevention: review infusion records for the substance requiring the most resources or clinical attention and assign the initial code to that substance. In chemotherapy encounters, 96413 is always primary when chemo is given.

Denial: Bundling with 96360 (double-billing concurrent hydration)

Reporting both 96360 (hydration initial) and 96368 for the same overlapping hydration drip is incorrect and will be denied or recouped on audit [2]. Prevention: when hydration runs concurrently with a therapeutic infusion, 96368 captures the hydration; 96360 is not additionally reported for the same drip.

Coding Scenarios

Scenario 1: Chemotherapy with simultaneous antiemetic

A patient receiving IV carboplatin at an outpatient oncology infusion center. Carboplatin infuses over 45 minutes beginning at 9:00 AM (stop 9:45 AM). Ondansetron 8 mg IV piggyback is initiated at 9:00 AM and runs for 30 minutes (stop 9:30 AM). Both infusions run simultaneously.

Correct coding: 96413 (carboplatin, chemo initial) + 96368 (ondansetron, concurrent)

Why: Carboplatin is the clinically dominant chemotherapy agent; 96413 is the initial code per chemo hierarchy. Ondansetron overlaps with carboplatin in clock time, making it a concurrent infusion (96368). Reporting 96365 for ondansetron as a separate initial would violate hierarchy rules; reporting 96367 would be incorrect because the times overlap.

Scenario 2: Multiple concurrent drugs, one unit only

During the same chemotherapy encounter, the patient receives cisplatin (primary, 96413), dexamethasone IV, and ondansetron IV, all three running simultaneously via Y-site for 30 minutes.

Correct coding: 96413 (cisplatin, chemo initial) + 96368 x 1 unit (captures all concurrent infusions combined)

Why: The MUE for 96368 is 1 per date of service. Two concurrent supportive drugs do not generate two units of 96368. Submitting 96368 x 2 triggers automated denial.

Scenario 3: Hydration running concurrently with therapeutic infusion

A patient presents for IV iron infusion (ferric carboxymaltose) at an infusion center. The iron infuses over 20 minutes. Simultaneously, NS 500 mL runs at the same time to address pre-infusion dehydration.

Correct coding: 96365 (IV iron, therapeutic initial) + 96368 (NS hydration, concurrent)

Why: The therapeutic drug (IV iron) drives the hierarchy; 96365 is the initial code. Hydration running at the same time is the concurrent service, captured by 96368. Reporting both 96360 and 96368 for the same concurrent hydration constitutes double billing.

Scenario 4: Same-day E/M with infusion and concurrent service

An established patient with worsening rheumatoid arthritis is seen in a rheumatology office. The physician performs a significant, separately identifiable evaluation with moderate medical decision making. The patient then receives IV methylprednisolone over 30 minutes; during the infusion, NS piggyback runs concurrently for the last 20 minutes. The physician is present in the office suite throughout.

Correct coding: 99214-25 + 96365 (methylprednisolone, initial) + 96368 (NS, concurrent)

Why: Modifier 25 on the E/M code documents that the evaluation was separate and significant beyond routine infusion supervision. 96365 is the therapeutic initial. 96368 captures the concurrent hydration with documented overlap in the nursing record.

Related Codes

• 96365: IV infusion, initial, up to 1 hour; most common primary code paired with 96368
• 96366: Each additional hour of the same primary infusion; add-on to 96365, reported alongside 96368 when the primary extends beyond 1 hour
• 96367: Additional sequential infusion, new substance, up to 1 hour; mutually exclusive with 96368 when infusions do not overlap in time
• 96360: IV hydration, initial; lower-hierarchy primary when no therapeutic drug is given; subordinate to 96365 when both are provided
• 96374: IV push, single or initial substance; primary code when infusion is bolus-delivered over 15 minutes or less
• 96375: IV push, each additional sequential substance; sequential push counterpart to 96368 for concurrent drip
• 96413: Chemotherapy IV infusion, up to 1 hour; primary code for chemo encounters; 96368 is the concurrent add-on

Sources

1. AMA CPT Code Set, CPT 96368 Descriptor and Guidelines — AMA, current. Official descriptor, add-on code parenthetical, hierarchy guidelines for 96360 to 96379.
2. CMS NCCI Policy Manual, Chapter 11, Drug Administration — CMS, annual update (2025/2026). Bundling rules, PTP edit pairs, concurrent vs. sequential infusion definitions.
3. CMS Medically Unlikely Edits (MUE) Tables, Practitioner Services — CMS, quarterly updates (2025/2026). MUE = 1 per DOS for CPT 96368.
4. CMS Medicare Claims Processing Manual, Chapter 12, Physician/Nonphysician Practitioners — CMS, current. Section 30.5: drug administration billing rules, incident-to requirements, supervision requirements.
5. CMS Hospital Outpatient Prospective Payment System (OPPS), APC Status Indicators — CMS, current. APC packaged status for 96368 in hospital outpatient setting.
6. CMS CY2025 Physician Fee Schedule Final Rule — Federal Register / CMS, November 2024. RVU adjustments; APC/OPPS status indicators; no structural revision to infusion hierarchy codes for 2025.
7. AAPC CPT 96368 Code Reference — AAPC, current. Code description and concurrent infusion coding guidance.
8. HHS OIG Work Plan, Infusion Services — HHS OIG, current. Compliance priorities for infusion billing; audit focus on drug administration codes and drug charge matching.